Therapeutic Asset Ratings

748 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Multiple Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Pediatric Multiple Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Pediatric Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Pemphigus Vulgaris	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Systemic Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
muc1 peptide-poly-iclc vaccine Colorectal Adenoma	National Cancer Institute (NCI)	P2	CCC (53)
muc1 peptide-poly-iclc vaccine Colorectal Tubulovillous Adenoma	National Cancer Institute (NCI)	P2	CCC (53)
Muc-1 Peptide Vaccine Colorectal Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Muc-1 Peptide Vaccine Lynch Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Primary Peritoneal Endometrioid Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine Cytomegalovirus Infection	City of Hope Medical Center	P2	CCC (53)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine Lymphatic System Disorder	City of Hope Medical Center	P2	CCC (53)
Neoantigen-Loaded Dc Vaccine Non-Small Cell Lung Carcinoma	The First Affiliated Hospital of Nanchang University	P2	CCC (53)
ose2101 Locally Advanced Cancer	GERCOR - Multidisciplinary Oncology Cooperative Group	P2	CCC (53)
ose2101 Ovarian Cancer	ARCAGY/ GINECO GROUP	P2	CCC (53)
Pneumococcal Polyvalent Vaccine Pregerminal Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Ptvg-Ar Castration-Resistant Prostate Carcinoma	University of Wisconsin, Madison	P2	CCC (53)
Ptvg-Hp Castration-Resistant Prostate Carcinoma	University of Wisconsin, Madison	P2	CCC (53)
Recombinant respiratory syncytial virus pre-fusion F protein antigen Respiratory Syncytial Virus Infectious Disease	Medical University of Vienna	P2	CCC (53)
Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter Advanced Clear Cell Renal Cell Carcinoma	Mayo Clinic	P2	CCC (53)
Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter Stage III Renal Cell Cancer AJCC v8	Mayo Clinic	P2	CCC (53)
RHOC PEPTIDE VACCINE RV001V Prostate Cancer	RhoVac APS	P2	CCC (53)
Survaxm Digestive System Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)

Showing 251 to 275 of 748 assets

PreviousPage 11 of 30Next